bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical pharmacists in primary care: Provider satisfaction and perceived impact on quality of care provided
Authors: Truong Havan , Kroehl Miranda E , Lewis Carmen , Pettigrew Robin , Bennett Marialice , Saseen Joseph J , Trinkley Katy E 
Published: June 2017

Purpose: The purpose of this study is to evaluate primary care provider satisfaction and perceived impact of clinical pharmacy services on the disease state management in primary care. Methods: A cross-sectional survey with 24 items and 4 domains was distributed anonymously to pharmacy residency program directors across the United States who were requested to forward the survey to their primary care provider colleagues. Primary care providers were asked to complete the survey. Results: A total of 144 primary care providers responded to the survey, with 130 reporting a clinical pharmacist within their primary care practice and 114 completing the entire survey. Primary care providers report pharmacists positively impact quality of care (mean = 5.5 on Likert scale of 1–6; standard deviation = 0.72), high satisfaction with pharmacy services provided (5.5; standard deviation = 0.79), and no increase in workload as a result of clinical pharmacists (5.5; standard deviation = 0.77). Primary care providers would recommend clinical pharmacists to other primary care practices (5.7; standard deviation = 0.59). Primary care providers perceived specific types of pharmacy services to have the greatest impact on patient care: medication therapy management (38.6%), disease-focused management (29.82%), and medication reconciliation (11.4%). Primary care providers indicated the most valuable disease-focused pharmacy services as diabetes (58.78%), hypertension (9.65%), and pain (11.4%). Conclusion: Primary care providers report high satisfaction with and perceived benefit of clinical pharmacy services in primary care and viewed medication therapy management and disease-focused management of diabetes, hypertension, and pain as the most valuable clinical pharmacy services. These results can be used to inform development or expansion of clinical pharmacy services in primary care.
Peptide-mediated mast cell activation: ligand similarities for receptor recognition and protease-induced regulation
Authors: Lu Lei , Kulka Marianna , Unsworth Larry D 
Published: June 2017

Abstract
MCs are crucial regulators of the innate immune response. MC degranulation is a rapid response mechanism that allows for the release of a stored plethora of inflammatory mediators, including histamine, heparin, various serine proteases, chemokines, and cytokines. The activation of MCs can lead to the de novo expression of a variety of chemokines and cytokines that can influence a variety of outcomes: inflammation, angiogenesis, and others. A variety of IgE-independent mediators, including IgG, cytokines, chemokines, exogenous molecules, drugs, and cationic peptides, and others, can directly trigger MC activation. For decades, various peptide stimuli, including peptide toxins, neuropeptides, antimicrobial peptides, and endogenous bioactive peptides, have been associated with MC allergic reactions in various physiologic and pathologic conditions. Recently, an activation mechanism has been established, whereby the MRGPRX2 receptor is involved in most of the peptide stimuli-related activation of human MCs. Interestingly, most of these peptide sequences seem to have a strong structural similarity that includes abundant positive charges and aromatic/aliphatic amino acids. In this review, we discuss the structures of known peptide stimuli and the receptors with which they interact for the express purpose of highlighting peptide elements as building blocks for tissue engineering applications.
Managing cancer and living meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer.
Authors: Rodin Gary , Lo Christopher , Rydall Anne , Nissim Rinat , Malfitano Carmine , Shnall Joanna , Zimmermann Camilla , Hales Sarah 
Published: June 2017

LBA10001 Background: Patients with advanced cancer experience substantial distress in response to the burden of disease and the challenge of living meaningfully in the face of impending mortality. We developed a novel, brief, manualized psychotherapeutic intervention called CALM designed to alleviate distress and facilitate adjustment in this population. CALM consists of 3-6 individual sessions delivered over 3-6 months and supports exploration in 4 broad domains: 1) symptom management and communication with health care providers; 2) changes in self and relations with close others; 3) sense of meaning and purpose; and 4) the future and mortality. Methods: Patients with advanced cancer were recruited from outpatient clinics at a comprehensive cancer center and randomized to receive either CALM or usual care (UC). Assessments of depressive symptoms (primary outcome), death-related distress and other secondary outcomes were conducted at baseline, 3 (primary endpoint) and 6 months. ANCOVA was used to test for outcome differences between groups at follow-up, controlling for baseline scores. Results: Three hundred and five participants were recruited and randomized (n = 151 CALM; n = 154 UC). Compliance with the intervention was 77.5% and attrition was 28% (16% deceased, 8% lost to follow-up, 4% withdrew). The CALM group reported less severe depressive symptoms compared to UC at 3 (ΔM1-M2 = 1.09, p < 0.04; Cohen’s d = 0.23) and 6 months (ΔM1-M2 = 1.33, p < 0.01; Cohen’s d = 0.29). Other statistically significant findings in psychological well-being and preparation for the end of life at 3- and 6- months also favored CALM vs UC. Conclusions: CALM is an effective intervention for patients with advanced cancer that provides a systematic approach to alleviate distress and to address predictable challenges. Clinical trial information: NCT01506492.
Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study.
Authors: Lambertini Matteo , Kroman Niels , Ameye Lieveke , Cordoba Octavi , Pinto Alvaro , Benedetti Giovanni , Jensen Maj-Britt , Gelber Shari I. , Del Grande Maria , Ignatiadis Michail , De Azambuja Evandro , Paesmans Marianne , Peccatori Fedro , Azim Jr. Hatem A. 
Published: June 2017

LBA10066 Background: Physicians and pts remain concerned on the safety of pregnancy following BC, particularly in women with history of ER+ disease. Previously, we showed no detrimental effect of pregnancy on BC outcome within the first 5 years following conception (Azim et al. JCO 2013). Here, we report long-term follow-up data. Methods: In this multicenter retrospective study, pts with pregnancy after BC (pregnant cohort) were matched (1:3) according to tumor and treatment characteristics with pts without subsequent pregnancy (non-pregnant cohort). To adjust for guaranteed time bias, each non-pregnant pt should have been disease free for a minimum time not inferior to the time elapsing between BC diagnosis and conception in the matched pregnant one. Primary endpoint was disease-free survival (DFS) in pts with ER+ BC. Secondary endpoints were DFS and overall survival (OS) in ER-negative and all pts irrespective of ER status. We also evaluated the impact of induced abortion on BC outcome. Results: The study included 1,207 pts, 333 pregnant and 874 non-pregnant. A total of 57% of pts had ER+ BC. After 12.5 years from conception, no DFS difference was observed between pregnant and non-pregnant pts with ER+ BC (hazard ratio [HR] 0.94; 95% confidence intervals [CI] 0.70-1.26; p = 0.68), ER- BC (HR 0.75; 95% CI 0.53-1.06; p = 0.10), and all pts (HR 0.85; 95% CI 0.68-1.06; p = 0.15). There was no OS difference between the 2 cohorts in pts with ER+ BC (HR 0.84; 95% CI 0.60-1.18; p = 0.32), but a significant improved OS was observed in the pregnant cohort for ER- pts (HR 0.57; 95% CI 0.36-0.90; p = 0.01) yielding a significant overall estimate (HR 0.72; 95% CI 0.55-0.94; p = 0.02). Abortion did not have any impact on outcome (HR 0.80; 95% CI 0.56-1.13; p = 0.20), irrespective of ER status. Conclusions: This is the largest study addressing the safety of pregnancy in pts with history of ER+ BC. Long-term follow-up confirms that pregnancy is safe and should not be discouraged irrespective of ER status. Our results further strengthen the rationale of the ongoing IBCSG-BIG-NABCG POSITIVE trial (NCT02308085) addressing the role of temporary interruption of adjuvant endocrine therapy to allow pregnancy.
Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.
Authors: Basch Ethan M. , Deal Allison Mary , Dueck Amylou C. , Bennett Antonia Vickery , Atkinson Thomas Michael , Scher Howard I. , Kris Mark G. , Hudis Clifford A. , Sabbatini Paul , Dulko Dorothy , Rogak Lauren J. , Barz Allison Emily , Schrag Deborah 
Published: June 2017

LBA2 Background: We previously reported significant benefits in quality of life, patient satisfaction, and emergency room utilization outcomes from a large single-center randomized controlled trial comparing web-based symptom monitoring with patient-reported outcomes (PROs) vs. usual care in patients receiving chemotherapy for metastatic solid tumors (Clinicaltrials.gov: NCT00578006). We now present overall survival results from this trial. Methods: Patients receiving routine outpatient chemotherapy for metastatic solid tumors at Memorial Sloan Kettering Cancer Center were randomly assigned to self-report 12 common symptoms via tablet computers (“PRO intervention”), or to usual care. Treating physicians received symptom printouts at visits and nurses received email alerts when participants reported severe or worsening symptoms. Overall survival was tabulated based on medical records and Social Security Death Index data, estimated using the Kaplan-Meier method, and compared between arms using a log-rank test and Cox proportional hazards regression adjusting for age, sex, race, education level, and cancer type. Results: Between September 2007 and January 2011, 766 patients were randomized, with median age 61 (range 26-91), 86% white, 58% female, and 22% with less than high school education. Cancer types included genitourinary (32% of patients), gynecologic (23%), breast (19%), and lung cancer (26%). Survival results were assessed in June 2016 after a median follow up of 7 years and 517/766 (67%) of participants had died. Median overall survival in the PRO intervention arm was 5 months longer than the control arm (31.2 vs. 26.0 months, p = 0.03). In the multivariable model, results remained statistically significant with a hazard ratio of 0.832 (p = 0.04; 95% CI; 0.696, 0.995). Conclusions: Systematic symptom monitoring during outpatient chemotherapy using web-based patient-reported outcomes confers overall survival benefits. These single-center results are being further evaluated in a national multicenter implementation trial. Clinical trial information: NCT00578006.
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
Authors: Scherpereel Arnaud , Mazieres Julien , Greillier Laurent , Dô Pascal , Bylicki Olivier , Monnet Isabelle , Corre Romain , Audigier-Valette Clarisse , Locatelli-Sanchez Myriam , Molinier Olivier , Thiberville Luc , Urban Thierry , Ligeza-poisson Catherine , Planchard David , Amour Elodie , Morin Franck , Moro-Sibilot Denis , Zalcman Gerard ,   French Cooperative Thoracic Intergroup (IFCT)
Published: June 2017

LBA8507 Background: To date, no treatment is recommended in MPM pts progressing after 1st-line pemetrexed-platinum doublet. Disease control rate (DCR) is <30% with all drugs tested in 2nd-line setting. Preliminary results suggested possible activity of anti-PD-1 mAb in 2nd/3rd-line, opposed to single agent anti-CTLA-4 mAb. Therefore anti-PD1 mAb efficacy deserves confirmation, and anti-PD-1 + anti-CTLA-4 combination value is currently unknown in MPM. Methods: In this multicenter randomized non comparative phase 2 trial, eligible pts had age>18, PS 0-1, histologically proven MPM relapsing after 1 or 2 prior lines including pemetrexed/platinum doublet, measurable disease. Randomized pts (1:1) received Nivo 3 mg/kg q2w, or Nivo 3 mg/kg q2w + Ipi 1 mg/kg q6w, until progression or unacceptable toxicity. Primary endpoint was DCR at 12 weeks with a blinded independent central review (BICR). 114 patients were to be randomized (with 108 eligible), with one-step Fleming procedure, H0 P<20% vs H1 P>40%, with 95% power, 5% one-sided a-risk: ≥17 failure-free pts had to be observed at 12 weeks in either arm, to conclude to the activity of the corresponding regimen. Results: From March to August 2016, 125 pts were enrolled in 21 centers. Males: 80%, median age: 71.8 years (range 32.5-88.1), PS 1: 62.4%, epithelioid 83.2%, 1 previous line: 69.6%; 70% of pts received ≥ 3 cycles of either treatment. Twelve weeks-DCR assessed by BICR in the first 108 eligible pts was 42.6% [IC95%: 29.4-55.8%] with Nivo (n=23/54), and 51.9% [38.5-65.2%] with Nivo+Ipi (n=28/54). ORR was 16.7% [6.7%-26.6%] with Nivo (n=9/54), and 25.9% [14.2-37.6%] with Nivo+Ipi (n=14/54). All grade/G3-4 toxicities were slightly increased in the combo arm (86.9%/16.4%) vs Nivo alone (77.8%/9.5%); 3 treatment-related deaths were observed in the combo arm (1 metabolic encephalopathy, 1 fulminant hepatitis, 1 acute renal failure). Full QoL, PFS and OS data will be presented at 2017 ASCO meeting. Conclusions: Both Nivo and Nivo+Ipi arms reached their endpoint in 2nd/3rd-line MPM pts, suggesting that immunotherapy may provide new options for these pts. Clinical trial information: NCT02716272.
Effect of Interscalene Brachial Plexus Block on the Pulmonary Function of Obese Patients: A Prospective, Observational Cohort Study
Authors: Melton M. Stephen , Monroe Hanni E. , Qi Wenjing , Lewis Stephanie L. , Nielsen Karen C. , Klein Stephen M. 
Published: June 2017

BACKGROUND:
The effect of interscalene block (ISB) on pulmonary function of obese participants has not been investigated. The goal of this study is to assess the association of obesity (body mass index [BMI] >29 kg/m2 vs BMI <25 kg/m2) and change in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) after ISB in participants undergoing outpatient shoulder surgery.

METHODS:
This prospective, observational cohort study compared obese (BMI >29 kg/m2) and normal-weight (BMI <25 kg/m2) groups undergoing ISB for ambulatory shoulder surgery, on preblock and postblock FVC and FEV1, at 30 minutes postblock and in the postanesthesia care unit (PACU). The primary outcome in this study was FVC% change (percentage change from preblock to postblock values of FVC) at 30 minutes postblock in the supine position. Secondary outcomes included FVC% change at PACU and in the sitting position, FEV1% change (percentage change from preblock to postblock values of FEV1), FVC, FEV1, incidence of diaphragmatic paresis, modified Borg scale for perceived dyspnea, Richmond Agitation-Sedation Scale scores for sedation, and intraoperative airway events.

RESULTS:
Fourteen participants were recruited to each group. The mean (standard deviation) BMI in the normal-weight and obese groups was 23 (1.7) and 33 (3.1) kg/m2, respectively. ISB success rate was 100%. All participants demonstrated hemidiaphragmatic paresis after ISB. Compared to the normal-weight group, in the sitting position, the obese group had a significant decrease in FVC% change at 30 minutes (−30 [10.5] vs −23 [7.2], P = .046) and an FEV1% change in the PACU (−40 [12.6] vs −27 [13.9], P = .02). No difference was found for measurements taken in the supine position. A repeated-measures analysis demonstrated that, adjusted for position, there is no significant group effect on FVC% change or FEV1% change from 30 minutes to PACU. The 2 groups were not different in terms of breathlessness and sedation at 30 minutes (P = .67, P = .48, respectively) and in the PACU (P = .69, P > .99, respectively) nor in the occurrence of intraoperative airway events (P > .99).

CONCLUSIONS:
ISB is associated with greater FVC and FEV1 reductions in obese participants undergoing shoulder surgery compared to normal-weight participants. Neither time (30 minutes versus PACU) nor position (sitting versus supine) affected this relationship. Despite these changes, obesity was not associated with increased clinical respiratory symptoms or events.
A mutation in keratin 18 that causes caspase-digestion resistance protects homozygous transgenic mice from hepatic apoptosis and injury
Authors: Yoon Han-Na , Yoon Sung-Yeon , Hong Jin-Hyuck , Ku Nam-On 
Published: June 2017

ABSTRACT
Cytoskeletal keratin 18 (K18) undergoes caspase-mediated digestion during apoptosis, which leads to dramatic disassembly of keratin filaments. We studied the significance of K18 caspase digestion in a mouse model and generated transgenic mice expressing the human K18 caspase digestion-resistant double-mutant K18-D238/397E in a mouse (m) K18-null background, and compared their response to injury mediated by administration of antibody against tumor necrosis factor receptor superfamily member 6 (Fas), anti-FasAb. Notably, K18-D238/397E;mK18-null mice were significantly more resistant to anti-FasAb-induced injury as compared with K18-WT;mK18-null mice (23% vs 57% lethality, respectively; P&lt;0.001). The same applied when the toxin microcystin-LR (MLR) was used to induce liver injury, i.e. lethality of K18-D238/397E;mK18-null mice in response to MLR treatment was reduced compared with the control mouse strain. The lesser rate of apoptosis in K18-D238/397E;mK18-null livers is associated with delayed degradation and, thus, sustained activation of cell-survival-related protein kinases, including stress-activated protein kinases and the NF-κB transcription factor, up to 6-8 h after administration of anti-FasAb. However, activation of the kinases and NF-κB in K18-WT-reconstituted livers decreases dramatically 8 h after anti-FasAb administration. In addition, the D238/397E double-mutation results in prolonged stability of K18 protein in transfected cells and transgenic livers. Therefore, our results show that the caspase digestion-resistant K18 helps to maintain keratin filament organization and delays apoptosis, thereby resulting in protection from liver injury.
A community proposal to integrate proteomics activities in ELIXIR
Authors: Vizcaíno Juan Antonio , Walzer Mathias , Jiménez Rafael C. , Bittremieux Wout , Bouyssié David , Carapito Christine , Corrales Fernando , Ferro Myriam , Heck Albert J.R. , Horvatovich Peter , Hubalek Martin , Lane Lydie , Laukens Kris , Levander Fredrik , Lisacek Frederique , Novak Petr , Palmblad Magnus , Piovesan Damiano , Pühler Alfred , Schwämmle Veit , Valkenborg Dirk , van Rijswijk Merlijn , Vondrasek Jiri , Eisenacher Martin , Martens Lennart , Kohlbacher Oliver 
Published: June 2017

Computational approaches have been major drivers behind the progress of proteomics in recent years. The aim of this white paper is to provide a framework for integrating computational proteomics into ELIXIR in the near future, and thus to broaden the portfolio of omics technologies supported by this European distributed infrastructure. This white paper is the direct result of a strategy meeting on ‘The Future of Proteomics in ELIXIR’ that took place in March 2017 in Tübingen (Germany), and involved representatives of eleven ELIXIR nodes. These discussions led to a list of priority areas in computational proteomics that would complement existing activities and close gaps in the portfolio of tools and services offered by ELIXIR so far. We provide some suggestions on how these activities could be integrated into ELIXIR’s existing platforms, and how it could lead to a new ELIXIR use case in proteomics. We also highlight connections to the related field of metabolomics, where similar activities are ongoing. This white paper could thus serve as a starting point for the integration of computational proteomics into ELIXIR. Over the next few months we will be working closely with all stakeholders involved, and in particular with other representatives of the proteomics community, to further refine this paper.
Contract Design by Service Providers with Private Effort
Authors: Zhang Hao , Kong Guangwen , Rajagopalan Sampath 
Published: June 2017

We investigate the performance of two commonly used pricing schemes—hourly-rate contract and two-part tariff—in service environments where the buyer’s valuation is invisible to the service provider and the provider’s effort may not be visible to the buyer. In the private effort environment, we further distinguish between situations where the contract may be based on the outcome or on the effort reported by the provider. We show that under the two-part tariff, when effort is private, the provider can achieve the same profit as under public effort by contracting on reported effort and will be worse off by contracting on outcome. Under the hourly-rate contract, compared with the public effort case, the provider may be better or worse off in keeping effort private and contracting on the reported effort, and the trade-off is affected by the degree of outcome uncertainty in a nontrivial way. We find that a provider’s profits under an hourly-rate contract are as good as under a two-part tariff over a sizable parameter regime when contracting on reported effort. The online appendix is available at https://doi.org/10.1287/mnsc.2017.2743 . This paper was accepted by Vishal Gaur, operations management.
Optimal Marketing Strategies for the Acquisition and Retention of Service Subscribers
Authors: Ben Rhouma Tarek , Zaccour Georges 
Published: June 2017

In this paper, we propose a diffusion model for a subscription service. The evolution over time of the number of subscribers is governed by a differential equation combining two processes—namely, a customer acquisition process and a customer attrition process. Assuming profit-maximization behavior of the firm, we use dynamic programming to optimize the customer equity and determine optimal customer relationship marketing expenditures. We implement an augmented Kalman filter with continuous state and discrete observations to estimate the model’s parameters using market data of two well-known companies in the telecommunications sector. To the best of our knowledge, this is the first paper to model acquisition and retention efforts in the context of a diffusion model. By doing so, we extend the literature on product diffusion to services—that is, beyond its traditional area of durable (and occasionally nondurable) products. By the same token, we contribute to the literature on customer relationship marketing (CRM), where social interactions have been overlooked. Our analytical and numerical results provide a better understanding of the relationships among the optimal customer equity, the customer lifetime value, the prospect lifetime value, and the optimal acquisition and retention spending. Our model and estimation approach give the tools for assessing empirically the role of CRM spending, social interactions, and other factors in the service subscription dynamics. Our main empirical results are as follows: (i) CRM spending and external incentives have indeed a significant effect on acquisition and retention processes; (ii) the impact of CRM is market specific; (iii) compared with optimal levels, both firms underinvest in retention; and (iv) whereas we observe increasing spending in acquisition over time, the derived optimal policy recommends a decreasing level of spending over time. This paper was accepted by Eric Anderson, marketing.